Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of mavrilimumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma

Next Previous
Trial Profile

Phase II study of mavrilimumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Apr 2020 According to an Kiniksa Pharmaceuticals media release, this study is expected to begin in the second half of 2020.
  • 17 Dec 2019 New trial record
  • 11 Dec 2019 According to a Kite Pharma media release, Kite and Kiniksa Pharmaceuticals, Ltd. announced clinical collaboration to conduct this study. Kite will be the sponsor of this study and will be responsible for conduct of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top